In this edition:
Quizartinib for newly diagnosed FLT3+ AML
Genetic factors driving primary mediastinal B-cell lymphoma
Pegaspargase for adult ALL/lymphoblastic lymphoma
Ponatinib and blinatumomab for ALL
CPX-351 for high-risk acute myeloid leukaemia
Impact of co-mutational patterns in NPM1-mutated AML
Dose-adjusted-EPOCH-R for newly diagnosed high-risk Burkitt lymphoma
Venetoclax regimens vs chemoimmunotherapy in CLL
Activated autologous natural killer cells ALL
CAR-T cell therapy in relapsed/refractory multiple myeloma
Please login below to download this issue (PDF)